{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:45:15Z","timestamp":1776779115308,"version":"3.51.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin J Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s40880-016-0102-6","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T09:35:14Z","timestamp":1461576914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China"],"prefix":"10.1186","volume":"35","author":[{"given":"Yunpeng","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaodong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,25]]},"reference":[{"key":"102_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"102_CR2","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588\u201394.","journal-title":"Cancer"},{"issue":"Suppl 3","key":"102_CR3","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, ESMO Guidelines Working Group. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25(Suppl 3):iii124\u201337.","journal-title":". Ann Oncol"},{"key":"102_CR4","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860\u20137.","journal-title":"Cancer"},{"key":"102_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/annonc\/mdi162","volume":"16","author":"RE Coleman","year":"2005","unstructured":"Coleman RE. Bisphosphonates in breast cancer. Ann Oncol. 2005;16:687\u201395.","journal-title":"Ann Oncol"},{"key":"102_CR6","first-page":"CD003474","volume":"2","author":"MH Wong","year":"2012","unstructured":"Wong MH, Stockler, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2012;2:CD003474.","journal-title":"Cochrane Database Syst Rev"},{"key":"102_CR7","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1200\/JCO.2005.11.931","volume":"23","author":"GN Hortobagyi","year":"2005","unstructured":"Hortobagyi GN. Progress in the management of bone metastases: one continent at a time? J Clin Oncol. 2005;23:3299\u2013301.","journal-title":"J Clin Oncol"},{"key":"102_CR8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082\u201390.","journal-title":"Cancer"},{"key":"102_CR9","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-13-2275","volume":"19","author":"C Palmieri","year":"2013","unstructured":"Palmieri C, Fullarton JR, Brown J. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clin Cancer Res. 2013;19:6863\u201372.","journal-title":"Clin Cancer Res"},{"key":"102_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2165\/00003495-200868040-00010","volume":"68","author":"S Dhillon","year":"2008","unstructured":"Dhillon S, Lyseng-Williamson KA. Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs. 2008;68:507\u201334.","journal-title":"Drugs"},{"key":"102_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000338947","volume":"35","author":"HB Sittig","year":"2012","unstructured":"Sittig HB. Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate. Onkologie. 2012;35:380\u20137.","journal-title":"Onkologie"},{"key":"102_CR12","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"GJ Morgan","year":"2010","unstructured":"Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376:1989\u201399.","journal-title":"Lancet"},{"key":"102_CR13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","volume":"29","author":"CH Poznak Van","year":"2011","unstructured":"Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29:1221\u20137.","journal-title":"J Clin Oncol"},{"key":"102_CR14","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","volume":"25","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464\u201372.","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"102_CR15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","volume":"11","author":"JR Gralow","year":"2013","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw. 2013;11(Suppl 3):S1\u201350.","journal-title":"J Natl Compr Canc Netw"},{"key":"102_CR16","unstructured":"The Committee of Rehabilitation and Palliative Care, China. Chinese expert consensus statement on clinical diagnosis and treatment of malignant tumor bone metastasis and bone related diseases. Beijing: Peking Union Medical College Press. 2007. (in Chinese)."},{"key":"102_CR17","unstructured":"The Committee of Rehabilitation and Palliative Care, China. Chinese expert consensus statement on clinical diagnosis and treatment of malignant tumor bone metastasis and bone related diseases. Beijing: Peking University of Medicine Press. 2014. (in Chinese)."},{"key":"102_CR18","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893\u2013917.","journal-title":"Int J Cancer"},{"key":"102_CR19","first-page":"87","volume":"4","author":"S Li","year":"2012","unstructured":"Li S, Peng Y, Weinhandl ED, Blaes AH, Cetin K, Chia VM, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012;4:87\u201393.","journal-title":"Clin Epidemiol."},{"issue":"3","key":"102_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40880-015-0042-6","volume":"34","author":"W Chen","year":"2015","unstructured":"Chen W, Zheng R, Zeng H, Zhang S. The updated incidences and mortalities of major cancers in China, 2011. Chin J Cancer. 2015;34(3):53.","journal-title":"Chin J Cancer."},{"key":"102_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","volume":"129","author":"M Yong","year":"2011","unstructured":"Yong M, Jensen A\u00d6, Jacobsen JB, N\u00f8rgaard M, Fryzek JP, S\u00f8rensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999\u20132007). Breast Cancer Res Treat. 2011;129:495\u2013503.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"102_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/pcan.2011.7","volume":"14","author":"N Sathiakumar","year":"2011","unstructured":"Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999\u20132006. Prostate Cancer Prostatic Dis. 2011;14(2):177\u201383.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"102_CR23","first-page":"53","volume":"45","author":"LD Rybak","year":"2001","unstructured":"Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med. 2001;45:53\u201364.","journal-title":"Q J Nucl Med"},{"key":"102_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-3-642-78596-2","volume-title":"Metastatic bone disease fundamental and clinical aspect","author":"IJ Diel","year":"1994","unstructured":"Diel IJ, Kaufmann M, Bastert G. Metastatic bone disease fundamental and clinical aspect. Berlin: Springer-Verlag; 1994. p. 93\u2013108."},{"key":"102_CR25","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314\u201321.","journal-title":"J Clin Oncol"},{"key":"102_CR26","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150\u20137.","journal-title":"J Clin Oncol"},{"key":"102_CR27","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458\u201368.","journal-title":"J Natl Cancer Inst"},{"key":"102_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3111\/13696998.2011.632044","volume":"15","author":"HJ Henk","year":"2012","unstructured":"Henk HJ, Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. J Med Econ. 2012;15:175\u201384.","journal-title":"J Med Econ"},{"key":"102_CR29","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1007\/s00520-013-1934-0","volume":"21","author":"T Wyngaert Van den","year":"2013","unstructured":"Van den Wyngaert T, Delforge M, Doyen C, Duck L, Wouters K, Delabaye I, et al. Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24\u00a0months in patients with multiple myeloma or bone metastases from solid tumors. Support Care Cancer. 2013;21:3483\u201390.","journal-title":"Support Care Cancer"}],"container-title":["Chinese Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-016-0102-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-016-0102-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T16:57:08Z","timestamp":1526144228000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancercommun.biomedcentral.com\/articles\/10.1186\/s40880-016-0102-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,25]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1186\/s40880-016-0102-6","relation":{},"ISSN":["1944-446X"],"issn-type":[{"value":"1944-446X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,25]]},"article-number":"40"}}